Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Gynecologic 5Thoracic 3CNS 3Other solid neoplasm 2Dermatologic 2Head & Neck 1

Conditions

Glioblastoma 2Melanoma 1Brain Neoplasms 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × defactinib × CNS × Clear all
NCT06630260 2026-01-21

5G-RUBY

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
182 enrolled
CNS

Glioblastoma

NCT05798507 2025-12-15

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Emory University

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
CNS

Glioblastoma

NCT06194929 2025-12-03

DETERMINE

University of Utah

Phase 1/2 Recruiting
33 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡